Posted by Michael Wonder on 08 Sep 2024
YolTech Therapeutics receives US FDA rare paediatric disease designation for YOLT-203 in treating primary hyperoxaluria type 1
4 September 2024 - YolTech Therapeutics today announced that the US FDA has granted rare paediatric disease designation to YOLT-203 for the treatment of primary hyperoxaluria type 1.
YOLT-203 is the world's first in vivo gene editing therapy specifically developed for primary hyperoxaluria type 1, utilising YolTech's proprietary YolCas12 gene editing technology.
